| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other income (expense), net | 847 | 906 | ||
| Net loss | -11,894 | -11,350 | ||
| Unrealized gain on available-for-sale securities, net of tax | 6 | - | ||
| Total other comprehensive income | 6 | - | ||
| Comprehensive loss | -11,888 | - | ||
| Net loss per share - basic | -0.64 | -0.61 | ||
| Net loss per share - diluted | -0.64 | -0.61 | ||
| Weighted-average common shares outstanding - basic | 18,701,708 | 18,701,286 | ||
| Weighted-average common shares outstanding - diluted | 18,701,708 | 18,701,286 | ||
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)